Will Pharma and Specialty Demand Boost Cardinal Health’s Q4 Results? – August 7, 2026
Key Takeaways
- Cardinal Health is expected to post Q4 sales of $65.61B, up 9.1%, with EPS projected to rise 16.4%.
- CAH’s Pharmaceutical and Specialty Solutions business likely stayed a key growth driver on strong demand.
- Cardinal Health’s GMPD unit faced tariff, inflation and customer volume pressures despite cost initiatives.
Cardinal Health (CAH – Free Report) is scheduled to report fourth-quarter fiscal 2027 results on Aug. 11, before market open.
The Zacks Consensus Estimate for sales is pegged at $65.61 billion, implying 9.1% year-over-year growth. The bottom line estimate is pinned at $2.42, suggesting growth of 16.4%.
The EPS estimates have remained stable over the past seven days.
The company delivered an earnings surprise of 13.21% in the last reported quarter. Its earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 10.27%.
What the Zacks Model Unveils
Our proven model predicts an earnings beat for Cardinal Health this time around. The combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. This is not the case here, as you will see below.
Earnings ESP: Earnings ESP, which represents the difference between the Most Accurate Estimate ($2.45 per share) and the Zacks Consensus Estimate is +1.24% for CAH. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: The company carries a Zacks Rank #2 at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Factors Likely to Have Driven Q4 Performance
Cardinal Health is expected to have delivered robust performance during the fourth quarter of fiscal 2026, supported by sustained momentum in its Pharmaceutical and Specialty Solutions business and continued strength across its higher-margin growth businesses. Pharmaceutical demand is likely to have remained healthy across specialty, branded, generic and consumer health products.
The ongoing expansion of the company’s specialty platform, including Solaris integration and its Specialty Alliance physician network, should have continued to boost revenue growth. Management had previously indicated that specialty revenues were growing at more than 20% and were expected to exceed $50 billion in fiscal 2026, suggesting that the segment likely remained a key driver of earnings.
Within the Pharmaceutical segment, profit growth is expected to have continued outpacing revenue growth, supported by favorable branded and specialty product contributions, resilient generic market dynamics, and preserved economics on distribution contracts despite Inflation Reduction Act (IRA)-related pricing changes. However, revenue growth may have remained moderate due to lower wholesale acquisition cost (WAC) pricing under the IRA, slower GLP-1 growth normalization and ongoing loss-of-exclusivity transitions.
The Global Medical Products and Distribution (GMPD) segment is likely to have remained a mixed performer. Continued growth in Cardinal Health-branded products, cost optimization initiatives and operational simplification should have supported underlying execution, although tariffs, selective customer volume losses and inflationary pressures on certain product categories may have continued weighing on profitability.
Meanwhile, the company’s Other businesses — At-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics — are expected to have sustained their robust growth trend, aided by strong demand, theranostics expansion, ADS integration synergies and logistics volume gains.
Continued investments in technology, automation and distribution infrastructure are also likely to have supported long-term growth. Cardinal Health’s disciplined capital allocation, ongoing share repurchases and resilient operating execution are expected to have supported another quarter of healthy earnings growth despite persistent pricing and tariff-related headwinds.
CAH Share Price Performance
In the year-to-date period, CAH shares have rallied 15.6%, outperforming its industry’s 4.8% growth over the same period.
CAH has also comfortably outpaced the S&P 500’s 12.7% gain, underscoring strong investor confidence in the company’s specialty momentum and expansion in theranostic and at-home services.
Image Source: Zacks Investment Research
CAH has also delivered markedly stronger returns than its MedTech peers. While McKesson (MCK – Free Report) has gained 6.2% year to date, Cencora (COR – Free Report) has declined 3.8%. The stock has also significantly outperformed the broader Zacks Medical sector, which has generated a modest 0.9% return during the same period.
CAH’s Key Valuation Metric
From a valuation standpoint, Cardinal Health is trading at a forward 12-month price-to-earnings (P/E) multiple of 19.5X, reflecting a premium valuation relative to its MedTech peers.
The elevated multiple suggests that investors are assigning a higher valuation to the company’s long-term growth prospects, particularly its specialty expansion and productivity gains from high-growth businesses.
CAH currently trades well above Cencora, which carries a forward 12-month P/E of 16.65X, and McKesson, which is valued at 18.84X sales.
Image Source: Zacks Investment Research
CAH’s Long-Term Investment Visibility
Cardinal Health’s focus on transforming its business toward higher-margin specialty healthcare services, while reinforcing the resilience of its core Pharmaceutical distribution franchise, is likely to drive long-term growth. Management continues to expand its Specialty platform through investments in specialty distribution, physician management services (MSOs), biopharma solutions and strategic acquisitions.
The integration of Solaris into the Specialty Alliance, continued expansion of its multi-specialty physician network through tuck-in acquisitions, and growing collaboration between Specialty Networks, MSOs and Nuclear businesses are expected to deepen customer relationships and drive above-market specialty growth.
The company also expects specialty revenues to exceed $50 billion in fiscal 2026, underscoring the increasing importance of this business to long-term earnings. Cardinal Health continues to strengthen its pharmaceutical distribution network through automation, productivity initiatives, and technology investments, enabling it to deliver record service levels while preserving distribution economics despite pricing changes under the Inflation Reduction Act (IRA).
Beyond Pharma, Cardinal Health is building multiple long-term growth engines across At-Home Solutions, Nuclear and Precision Health Solutions, and OptiFreight Logistics, all of which continue to benefit from favorable healthcare trends. The company is investing to expand its home health distribution capacity, integrate ADS, grow the ContinuCare Pathway program, and capitalize on the ongoing shift toward home-based care.
Cardinal Health’s Nuclear and Precision Health Solutions segment continues to strengthen its position in theranostics through increased Actinium-225 production capacity and expanding pharmaceutical collaborations, supporting future growth as targeted cancer therapies gain traction. At the same time, the company is advancing enterprise-wide initiatives focused on operational efficiency, supply-chain resilience, prudent capital deployment, and selective acquisitions, while pursuing a multiyear turnaround effort in GMPD. Combined with robust cash flow, continued buybacks, technology investments, and a growing mix of higher-margin businesses, these efforts should support durable earnings growth and long-term value creation for shareholders.
